Caenorhabditis elegans in Parkinson's disease drug discovery: Addressing an unmet medical need

Molecular Interventions

Volumn 8, Issue 6, 2008, Pages 284-293

  Nass, Richard ^a   Merchant, Kalpana M ^b   Ryan, Timothy ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BROMOCRIPTINE; COLISTIMETHATE; DEXTROMETHORPHAN; DIHYDREXIDINE; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; NEUROTOXIN; PARKIN; QUINPIROLE; DOPAMINE; DRUG;

CAENORHABDITIS ELEGANS; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; DRUG IDENTIFICATION; DRUG MECHANISM; GENE IDENTIFICATION; HIGH THROUGHPUT SCREENING; HUMAN; LEWY BODY; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA; ANIMAL; ANIMAL MODEL; DRUG DEVELOPMENT; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; CAENORHABDITIS ELEGANS; DOPAMINE; DRUG DISCOVERY; HUMANS; MODELS, ANIMAL; PARKINSON DISEASE; PHARMACEUTICAL PREPARATIONS;

EID: 58549095658     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.8.6.6     Document Type: Review

References (83)

1. Parkinson, J. An essay on the shaking palsy. Sherwood, Neely and Jones, London (1817).
2. Adler, C.H. Nonmotor complications in Parkinson's disease. Mov. Disord. 20, S23-S29 (2005).
3. Fahn, S. Clinical aspects of Parkinson disease, in Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems (Nass, R. and Przedborski, S. eds) pp 3-9, Academic Press, Boston (2008).
4. Merchant, K.M., Chesselet, M.-F., Hu, S.-C., and Fahn, S. Animal models of Parkinson's disease to aid drug discovery and development, in Animal and Translational Models for CNS Drug Discovery, Vol. 2 Neurological Disorders (McArthur, R. and Borsini, F. eds), Academic Press, Boston (2008).
5. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., et al. Brain dopamine and the syndrome of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455 (1973).
6. Au, W.L. and Calne, D.B. Pharmacotherapy and treatment of Parkinson's disease, in Contemporary Neuropharmacology (Sibley, D.R., Hanin, I., Kuhar, M., and Skolnick, P. eds) pp 479-522 John Wiley and Sons, Hoboken (2007).
7. Testa, C.M. Parkinson's disease: Genetics and pathogenesis, in Contemporary Neuropharmacology (Sibley, D.R., Hanin, I., Kuhar, M., and Skolnick, P. eds) pp 523-565 (2007).
8. Ross, O.A., Braithwaite, A.T., and Farrer, M.J. Genetics of Parkinson's disease, in Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems (Nass, R. and Przedborski, S. eds) pp 9-34, Academic Press, Boston (2008).
9. Mitchell, S.L., Kiely, D.K., Kiel, D.P., and Lipsitz, L.A. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson's disease. J. Amer. Geriatr. Soc. 44, 394-399 (1996).
10. Jorgensen, E.M. and Mango, S.E. The art and design of genetic screens: Caenorhabditis elegans. Nat. Rev. Genet. 3, 356-369 (2002).
11. Thiruchelvam, M., McCormack, A., Richfield, E.K., Baggs, R.B., Tank, A.W., Di Monte, D.A., and Cory-Slechta, D.A. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur. J. Neruosci. 18, 589-600 (2003).
12. Hoglinger, G.U., Oerte, W.H., and Hirsch, E.C. The rotenone model of parkinsonism - the five year inspection. J. Neural Transm. Suppl. 70, 269-270 (2006).
13. Chesselet, M. and Fernagu P. Environmental explorations of PD using rodent genetic models, in Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems (Nass, R. and Przedborski, S. eds) pp 285-294, Academic Press, Boston (2008).
14. Di Monte, D. Paraquat-induced neurodegeneration: A model of Parkinson' disease risk factors, in Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems (Nass, R. and Przedborski, S. eds) pp 207-218 Academic Press, Boston (2008).
15. Chia, S.E., Foo, S.C., Gan, S.L., Jeyaratnam, J., and Tian, C.S. Neurobehavioral functions among workers exposed to manganese ore. Scand. J. Work Environ. Health 19, 264-270 (1993).
16. Witholt, R., Gwiazda, R.H., and Smith, D.R. The neurobehavioral effects of subchronic manganese exposure in the presence and absence of pre-parkinsonism. Neurotoxicol. Teratol. 22, 851-861 (2000).
17. Stredrick, D.L., Stokes, A.H., Worst, T.J., Freeman, W.M., Johnson, E.A., Lash, L.H., Aschner, M., and Vrana, K.E. Manganese-induced cytotoxicity in dopamine-producing cells. Neurotoxicology 25, 543-553 (2004).
18. Clamp, M., Fry, B., Kamal, M., Xie, X., Cuff, J., Lin, M.F., Kellis, M., Lindblad-Toh, K., and Lander, E.S. Distinguishing protein-coding and noncoding genes in the human genome. Proc. Natl. Acad. Sci. 104, 19428-19433 (2007).
19. Hiller, L.W., Coulson, A., Murray, J.I., Bao, Z., Sulston, J.E., and Waterson, R.H. Genomics in C. elegans: So many genes, such a little worm. Genome Res. 15, 1651-1660 (2006).
20. The C. elegans Sequencing Consortium. Genome sequence of the nematode C. elegans: A platform for investigating biology. Science 282, 2012-2018 (1998).
21. Rand, J.B. and Nonet, M.L. Synaptic transmission, in C. elegans II. (Riddle, D.L., Blumenthal, T., Meyer, B.J., and Priess, J.R. eds) pp 611-643 Cold Spring Harbor Laboratory Press, New York (1997).
22. Thomas, J.H. and Lockery, S.H. Neurobiology, in C. elegans: A Practical Approach (Hoe, I.A. ed) pp 143-179 Oxford Univ. Press, New York (1999).
23. Bargmann, C.I. Neurobiology of the Caenorhabditis elegans genome. Science 82, 2028-2033 (1998).
24. Nass, R. and Blakely, R.B. The Caenorhabditis elegans dopaminergic system: Opportunities for insights into dopamine transport and neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 43, 521-544 (2003).
25. Faber, P.W., Alter, J.R., MacDonald, M.E., and Hard, A.C. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. 101, 6403-6408 (1999).
26. Nass, R., Hall, D.H., Miller, D.M., and Blakely, R.D. Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc. Natl. Acad. Sci. 99, 3264-3269 (2002).
27. Link, C.D. Transgenic invertebrates models of age-associated neurodegenerative diseases. Mech. Ageing Dev. 122, 1639-1649 (2001).
28. Rand, J.B. and Johnson C.D. Genetic pharmacology: Interactions betwen drugs and gene products in Caenorhabditis elegans. in Methods Cell Biol. 48, 187-204 (1995).
29. Artal-Sanz, M., de Jong, L., and Tavernarakis, N. Caenorhabditis elegans: A versatile platform for drug discovery. Biotechnol. J. 1, 1405-1418 (2006).
30. C. elegans II. (Riddle D.L., Blumenthal, T., Meyer, B.J., and Priess, J.R. eds) Cold Spring Harbor Laboratory Press, New York (1997).
31. Wood, W.B. Introduction to C. elegans, in The Nematode Caenorhabditis elegans (Wood, E.B. ed) pp 1-16 Cold Spring Harbor, New York (1988).
32. White, J.G., Southgate, E., Thompson, J.N., and Brenner, S. The structure of the ventral nerve cord of Caenorhabditis elegans. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 275, 327-348 (1976).
33. Bloom, L. Genetic and molecular analysis of genes required for axon outgrowth in Caenorhabditis elegans. PhD Thesis, Massachusetts Institute of Technology, Cambridge, MA (1993).
34. Christensen, M., Estevez, A., Yin, X., Fox, R., Morrison, R., McDonnell, M., Gleason, C., Miller, D.M., and Strange, K. A primary culture system for functional analysis of C. elegans neurons and muscle cells. Neuron 33, 503-514 (2002).
35. Bianchi, L. and Driscoll, M. Culture of embryonic C. elegans cells for electrophysiological and pharmacological analyses (September 30, 2006), WormBook, ed. The C. elegans Research Community, WormBook, doi/10.1895/wormbook.1.122.1, www.wormbook.org.
36. Fox, R.M., von Stetina, S.E., Barlow, S.J., Shaffer, C., Olszewski, K.L., Moore, J.H., Dupuy, D., Vidal, M., and Miller, D.M., 3rd A gene expression fingerprint of C. elegans embryonic motor neurons. BMC Genomics 6, 42 (2005).
37. Jorgensen, E.M. and Mango, S.E. The art and design of genetic screens: Caenorhabditis elegans. Nat. Rev. Genet. 3, 356-369 (2002).
38. Wicks, S.R., Yeh, R.T., Gish, W.R., Waterston, R.H., and Plasterk, R.H. Rapid gene mapping in Caenorhabditis elegans using a high density polymorphism map. Nat. Genet. 28, 160-164 (2001).
39. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
40. Montgomery, M.K., Xu, S., and Fire, A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Natl. Acad. Scie. 95, 15502-15507 (1998).
41. Timmons, L. and Fire, A. Specific interference by ingested dsRNA. Nature 395, 854 (1998).
42. Boutros, M. and Ahringer, J. The art and design of genetic screens: RNA interference. Nat. Rev. Genet. 9, 554-566 (2008).
43. Sulston, J., Dew, M., and Brenner, S. Dopaminergic neurons in the nematode Caenorhabditis elegans. J. Comp. Neurol. 163, 215-226 (1975).
44. Nass, R., Miller, D.M., and Blakely, R.D. C. elegans: A novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Relat. Disord. 7, 185-191 (2001).
45. Wintle, R.F. and Van Tol, H.H. Dopamine signaling in Caenorhabditis elegans: Potential for parkinsonism research. Parkinsonism Relat. Disord. 7, 177-183. (2001).
46. Ved, R., Saha, S., Westlund, B. et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280, 42655-42668 (2005).
47. Marvanova, M., Ding, T., Fullard, M., and Nass, R. Incorporating toxicogenetics to evaluate environmental neurotoxins: DA neuron cell death in C. elegans models of human manganism and amytrophic lateral sclerosis/ parkinsonism dementia complex. (unpublished results).
48. Nass, R. and Settevari, R. C. elegans models of Parkinson's disease: A robust genetic system to identify and characterize endogenous and environmental components involved in dopamine neuron degeneration, in Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems (Nass, R. and Przedborski, S. eds) pp 347-360, Academic Press, Boston (2008).
49. Nass, R. Manganese-induced dopamine neurodegeneration in C. elegans: Pharmacogenetic analysis in a novel model of manganism. (unpublished results).
50. Polymeropoulos, M.H., Lavedan, C., Leroy, E. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
51. Lotharius, J., Barg, S., Wiekop, P. Lundberg, C., Raymon, H.K., and Brundin, P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 38884-38894 (2002).
52. Kahle, P.J., Neumann, M., Ozmen, L. et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373 (2000).
53. Lee, F.J., Liu, F., Pristupa, Z.B., and Niznik, H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916-926 (2001).
54. Fortin, D., Nemani, V.M., and Edwards, R.H. The Dynamics of alpha-synuclein at the nerve terminal, in Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems (Nass, R. and Przedborski, S. eds) pp 237-246, Academic Press, Boston (2008).
55. Lakso, M., Vartianen, S., Moilanen, A.M., Sirvio, J., Thomoas, J.H., Nass, R., Blakely, R.D., and Wong, G. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α-synuclein. J. Neurochem. 86, 165-172 (2003).
56. Cooper, A.A., Gitler, A.D., Casikar, A. et al. α-synuclein blocks ER-golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-328 (2006).
57. Vartiainen, S., Pehkonen, P., Lakso, M., Nass, R., and Wong, G. Identification of gene expression changes in transgenic C. elegans overexpressing human α-synuclein. Neurobio. Dis. 22, 477-486 (2006).
58. Nass, R. and Nichols, C.D. Invertebrates as powerful genetic models for human neurodegenerative disease, in Handbook of Contemporary Neuropharmacology (Sibley, D.R., Hanin, I., Kuhar, M., and Skolnick, P. eds) pp 567-588 John Wiley and Sons, Hoboken (2007).
59. Shimura, H., Hattori, N., Kubo, S. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302-305 (2000).
60. Springer, W., Hoppe, T., Schmidt, E., and Baumeister, R. A Caenorhabditis elegans parkin mutant with altered solubility couples α-synuclein aggregation to proteotoxic stress. Hum. Mol. Genet., 14, 3407-3423 (2005).
61. Wolozin, B., Saha, S., Guillily, M., Ferree, A., and Riley, M. Investigating convergent actions of genes linked to familiar Parkinson's disease. Neurodegener. Dis. 5, 3-4 (2008).
62. Nass, R., Hahn, M.K., Jessen, T., McDonald, P.W., Carvelli, L., and Blakely, R.D. A genetic screen in Caenorhabditis elegans for dopamine neuron insensitivity to 6-hydroxydopamine identifies dopamine transporter mutants impacting transporter biosynthesis and trafficking. J. Neurochem. 94, 774-785 (2005).
63. Kaletta, T. And Hengartner, M.O. Finding function in novel targets: C. elegans as a model organism. Nat. Rev. Drug Discov. 5, 387-398 (2006).
64. van Ham, T.J., Thijssen, K.L., Breitling, R., Hofstra, R.M.W., Plasterk, R.H.A., and Nollen, E.A.A. C. elegans model identifies genetic modifiers of α-synuclein inclusion formation during aging. PLoS Genet. 4, e10000027 (2008).
65. Hamamichi, S., Rivas, R.N., Knight, A.L., Cao, S., Caldwell, K.A., and Caldwell, G.A. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc. Natl. Acad. Sci. 105, 728-732 (2008).
66. Sugimoto, A. High-throughput RNAi in C. elegans: Genome-wide screens and functional genomics. Differentiation 72, 81-91 (2004).
67. Settivari, R., Calley, J., Harlow, H., Zhang, J., Merchant, K.M., and Nass, R. Genetic and biochemical analysis of mortalin and other candidate proteins identified by proteomic analysis of postmortem brains in C. elegans models of Parkinson's disease. (unpublished results).
68. Nass, R. and Hamza, I. The nematode C. elegans as an animal model to explore toxicology in vivo: Solid and axenic growth culture conditions and compound exposure parameters. Curr. Protoc. Toxicol. doi: 10.1002/0471140856.tx0109s31 (2007).
69. Nass, R. C. elegans genetic strategies to identify novel Parkinson's disease-associated therapeutic targets and leads, in Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems (Nass, R. and Przedborski, S. eds) pp 261-68 Academic Press, Boston (2008).
70. Tatsumi, M., Groshan, K., Blakely, R.D., and Richelson, E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340, 249-258 (1997).
71. Tatsumi, M., Jansen, K., Blakely, R.D., and Richelson, E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur. J. Pharmacol. 368, 277-283 (1999).
72. Zhang, Y., Ma, C., Delohery, T., Nasipak, B., Foat, B.C., Bounoutas, A., Bussemaker, H.J., Kim, S.K., and Chalfie, M. Identification of genes expressed in C. elegans touch receptor neurons. Nature 418, 331-335 (2002).
73. McLaughlin, B. Dopamine neurotoxicity and neurodegeneration, in Molecular Mechanisms of Neurodegenerative Disease (Chesselet, M. ed.) pp 195-231 Humana Press, New Jersey (2001).
74. Horrobin, D.F. Realism in drug discovery - could Cassandra be right? Nat. Biotechnol. 19, 1099-1100 (2001).
75. Liebler, D.C. and Guengerich, F.P. Elucidating mechanisms of drug-induced toxicity. Nat. Rev. Drug Discov. 4, 410-420 (2005).
76. Guengerich, F.P. and MacDonald, J.S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20, 344-369 (2007).
77. Carroll, P.M., Fitzgerald, K., and Kindt, R. Mechanism of action in model organisms: Interfacing chemistry, genetics and genomics, in Model Organisms in Drug Discovery pp 153-183 John Wiley and Sons, Holboken (2003).
78. Peterson, R.T., Nass, R., Boyd, W.A., Freedman, J.H., Dong, K., and Narahashi, T. Use of non-mammalian alternative models for neurotoxicological study. Neurotoxicology 29, 546-555 (2008).
79. Ashrafi, K., Chang, F.Y., Watts, J.L., Fraser, A.G., Kamath, R.S., Ahringer, J., and Ruvkun, G. Genome-wide RNAi analysis of C. elegans fat-regulating genes. Nature 421, 220-221 (2003).
80. Rea, S.L., Wu, D., Cypser, J.R., Vaupel, J.W., and Johnson, T.E. A stress-sensitive reporter predicts longevity in isogenic populations of Caenorhabditis elegans. Nat. Genet. 37, 894-898 (2005).
81. Dupuy, D., Bertin, N., Hidalgo, C.A. et al.Genome-scale analysis of in vivo spatiotemporal promoter activity in Caenorhabditis elegans. Nat. Biotechnol. 25, 663-668 (2007).
82. Pujol, N., Cypowyj, S., Ziegler, K, Millet, A., Astrain, A., Goncharov, A., Jin, Y., Chisholm, A.D., Ewbank, J.J. Distinct innate immune responses to infection and wounding in the C. elegans epidermis. Curr. Biol. 18, 481-489 (2008).
83. Rohde, C.B., Zeng, F., Gonzalez-Rubio, R., Angel, M., and Yanik, M.F. Microfluidic system for on-chip high-throughput whole-animal sorting and screening at subcellular resolution. Proc. Natl. Acad. Sci. 104, 13891-13895 (2007).